PMID- 14969840
OWN - NLM
STAT- MEDLINE
DCOM- 20040615
LR  - 20061115
IS  - 1499-3872 (Print)
VI  - 3
IP  - 1
DP  - 2004 Feb
TI  - Dual fluorescence in situ hybridization in detection of HER-2 oncogene 
      amplification in primary hepatocellular carcinoma.
PG  - 62-8
AB  - BACKGROUND: Molecular cytogenetics of oncogene HER-2 amplification in primary 
      hepatocellular carcinoma (HCC) is still unknown. The aim of this study was to 
      investigate the frequency of HER-2 oncogene amplification in primary HCC and its 
      relations to clinicopathological parameters and prognosis. METHODS: Forty-two 
      surgical samples from patients with primary HCC were detected for their HER-2 
      oncogene amplification. The number of chromosome 17 and their ratio were tested 
      by dual fluorescence in situ hybridization (FISH) technique, and then the 
      correlations between HER-2 amplification, clinicopathological characteristics and 
      prognosis were analyzed statistically. RESULTS: HER-2 oncogene amplification was 
      detected in 9 (21.4%) of the 42 primary HCCs, including 4 patients with high copy 
      (HC) (9.5%) and 5 patients with low copy (LC) (11.9%). HER-2 amplification was 
      associated significantly with tumor size and postoperative survival time of HCC 
      patients (P<0.05), and the presence of HER-2 gene amplification was correlated 
      with postoperative relapse (P=0.257), but not related to sex, age, AFP level, HBV 
      infection, histopathological grading and clinical staging of HCC patients 
      (P>0.05). The HER-2 oncogene copy was examined in 31 (73.8%) of the 42 primary 
      HCCs, consisting of 9 patients with HER-2 amplification (21.4%) and 22 patients 
      with aneuploidy (52.4%). No significant relations were observed between the HER-2 
      oncogene copy, patient sex, tumor size, histopathological grading, clinical 
      staging, postoperative relapse and survival time (P>0.05); but the HER-2 oncogene 
      copy was correlated significantly to age, AFP level and HBV infection (P<0.05). 
      CONCLUSIONS: There are a lower frequency of HER-2 oncogene amplification and a 
      higher frequency of chromosome 17 aneuploidy in primary HCC. HER-2 oncogene 
      amplification may be involved in the development and progression of large HCC in 
      some patients, and seems to be a valuably independent prognostic factor 
      predicting the recurrence and poor survival in patients with large HCC.
FAU - Huang, Tie-Jun
AU  - Huang TJ
AD  - Research Department, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, 
      China.
FAU - Huang, Bi-Jun
AU  - Huang BJ
FAU - Liang, Qi-Wan
AU  - Liang QW
FAU - Huang, Chu-Wen
AU  - Huang CW
FAU - Fang, Yan
AU  - Fang Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Hepatobiliary Pancreat Dis Int
JT  - Hepatobiliary & pancreatic diseases international : HBPD INT
JID - 101151457
SB  - IM
MH  - Adult
MH  - Biopsy, Needle
MH  - Carcinoma, Hepatocellular/*diagnosis/genetics/surgery
MH  - Cohort Studies
MH  - Culture Techniques
MH  - Female
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Hepatectomy/methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Liver Neoplasms/*diagnosis/genetics/surgery
MH  - Male
MH  - Middle Aged
MH  - Oncogenes/genetics
MH  - Prognosis
MH  - Sensitivity and Specificity
EDAT- 2004/02/19 05:00
MHDA- 2004/06/16 05:00
CRDT- 2004/02/19 05:00
PHST- 2004/02/19 05:00 [pubmed]
PHST- 2004/06/16 05:00 [medline]
PHST- 2004/02/19 05:00 [entrez]
AID - 180 [pii]
PST - ppublish
SO  - Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):62-8.